Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
Aortic stenosis (AS) is a fatal disease if not treated promptly, especially in the older population. There is a need of multidisciplinary team approach for the comprehensive diagnosis, staging, risk stratification and treatment involving patient preferences, in order to optimize the management of this insidious disease. Studies have suggested that TAVR can be used as an alternative for SVAR in high risk as well as low risk patients with severe AS. Additionally, guidelines have underlined the benefits of TAVR with many terms and conditions.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
Measuring HbA1c has been the method of choice to assess glucose control; however, it does not reflect potential glucose excursions leading to hypoglycemia or postprandial hyperglycemia, which increase the risk of long-term complications, as well as overall glycemic variability. Continuous glucose monitoring (CGM) technology can circumvent some of these issues in T2DM management by providing near real-time glucose concentrations derived from interstitial fluid; and studies with CGM have demonstrated its efficacy and safety in this setting.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Addressing iron deficiency (ID) in patients with heart failure (HF) has become an important aspect of optimizing guideline-directed care in HF, as outlined by recent evidence and updated guidelines. During this webinar, expert faculty utilize challenging cases to discuss the importance of addressing ID in HF, as well as practical considerations for the diagnosis and treatment of ID in this setting.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Iron deficiency (ID) with or without anemia is a common and important comorbidity in patients with heart failure (HF), and it can have significant impacts on morbidity and mortality. Despite this burden, the diagnosis and assessment of ID is not widely sought by clinicians that see patients with HF, leading to underdiagnosis, misdiagnosis, and delayed treatment. Recent trials and evidence have shown that i.v. iron repletion in HF patients with ID can improve symptoms, quality of life, and outcomes, and this evidence has been reflected accordingly in the updated HF guidelines.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
The co-occurrence of diabetes and obesity is now commonly termed “diabesity”- a new worldwide epidemic. Several studies have corroborated the fact that weight loss can be an effective strategy to mitigate the risk of obesity-related comorbidities, including risk of type 2 diabetes and cardiovascular mortality, leading to improvements in lipid profile, blood pressure, severity of obstructive apnea, and health-related quality of life. This clinical brief, gives an overview of a live session, presented by Dr.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
Utilizing thought-provoking and interactive discussions, multidisciplinary experts in this masterclass cover advances in lifestyle, nutrition, genetics, and pharmacotherapy to prevent and address obesity, cardiovascular disease, hypertension, dyslipidemia, type 2 diabetes, kidney disease and more. Each section will include expert panel discussions, which will aim to provide practical approaches to patient management and interpret the latest advances to patient care.
- CMHC
- TME
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Immune thrombocytopenic purpura (ITP) is an autoimmune bleeding disorder that is characterized by suboptimal platelet count, purpura and hemorrhage. The burden of ITP is significant, leading to considerable mortality and life-threatening events such as intracranial hemorrhage and septicemia, if untreated, as well as reduction in health-related quality of life.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
ATTR cardiac amyloidosis (ATTR-CM) is a complex disease that remains challenging to diagnose and treat, and disproportionally affects African American patients. Low awareness about the disease, and limited therapeutic options are significant barriers to optimal care, however, significant advances have been made in the development of novel targeted-therapeutics that may improve patient outcomes. This clinical brief will review some of those advances in order to increase awareness about current gaps and disparities in ATTR-CM.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
Patients with a recent myocardial infarction (MI) are at very high-risk for future atherosclerotic cardiovascular disease (ASCVD) events, however, targeted LDL-C goal achievement and optimization of lipid lowering therapy (LLT) in these patients remains suboptimal. In turn, these gaps perpetuate the risk of future adverse events that patients with a recent MI will experience.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
Recent advances in the understanding of CKD progression in patients with type 2 diabetes have opened up new avenues of treatment that can potentially address some of the challenges and decrease cardiorenal risk in these patients. Of note, novel non-steroidal mineralocorticoid receptor antagonists (MRAs) are important new agents in this setting and have been recently FDA approved. During this activity, experts will discuss the recent advances with nonsteroidal MRAs in patients with type 2 diabetes and CKD, as well as their potential application to patient care.